| FF-10502 |
Article |
FF-10502, an antimetabolite with novel activity on dormant cells, is superior to gemcitabine for targeting pancreatic cancer cells |
Read Article |
| FF-10502 |
Article |
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors |
Read Article |
| FF-10832 |
Article |
FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model |
Read Article |
| FF-10832 |
Article |
A liposomal gemcitabine, FF-10832, improves plasma stability, tumor targeting, and antitumor efficacy of Gemcitabine in pancreatic cancer xenograft models |
Read Article |
| FF-10832 |
Article |
A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832 |
Read Article |
| FF-10832 |
Poster |
FF-10832 combined with immune checkpoint blockade shows favorable antitumor activity (AACR 2019) |
Download Poster |
| FF-10832 |
Poster |
A phase 1, first-in-human, dose escalation & biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors |
Download Poster |
| FF-10832 |
Poster |
A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with Pembrolizumab in patients with advanced solid tumors |
Download Poster |
| FF-10850 |
Article |
Optimization of dihydrosphingomyelin/cholesterol mol ratio in topotecan-loaded liposomes to enhance drug retention and plasma half-life by understanding physicochemical and thermodynamic properties of the lipid membrane |
Read Article |
| FF-10850 |
Article |
FF-10850, a novel liposomal topotecan achieves superior antitumor activity via macrophage- and ammonia-mediated payload release in the tumor microenvironment |
Read Article |
| FF-10850 |
Article |
Quantification of unencapsulated drug in target tissues demonstrates pharmacological properties and therapeutic effects of liposomal topotecan (FF-10850) |
Read Article |
| FF-10850 |
Poster |
A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors |
Download Poster |
